01 Oct 2025
bởiElaine Soliven
A single dose of clesrovimab, a long-acting monoclonal antibody, significantly reduced the incidence of respiratory syncytial virus (RSV)-associated medically attended lower respiratory infections (LRIs) and hospitalizations in healthy infants, according to the phase IIb–III CLEVER trial.